These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16672361)

  • 1. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax.
    Vietri NJ; Purcell BK; Lawler JV; Leffel EK; Rico P; Gamble CS; Twenhafel NA; Ivins BE; Heine HS; Sheeler R; Wright ME; Friedlander AM
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7813-6. PubMed ID: 16672361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.
    Vietri NJ; Purcell BK; Tobery SA; Rasmussen SL; Leffel EK; Twenhafel NA; Ivins BE; Kellogg MD; Webster WM; Wright ME; Friedlander AM
    J Infect Dis; 2009 Feb; 199(3):336-41. PubMed ID: 19099484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.
    Heine HS; Bassett J; Miller L; Hartings JM; Ivins BE; Pitt ML; Fritz D; Norris SL; Byrne WR
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1373-9. PubMed ID: 17296745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postexposure prophylaxis against experimental inhalation anthrax.
    Friedlander AM; Welkos SL; Pitt ML; Ezzell JW; Worsham PL; Rose KJ; Ivins BE; Lowe JR; Howe GB; Mikesell P
    J Infect Dis; 1993 May; 167(5):1239-43. PubMed ID: 8486963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.
    Sivko GS; Stark GV; Tordoff KP; Taylor KL; Glaze E; VanRaden M; Schiffer JM; Hewitt JA; Quinn CP; Nuzum EO
    Vaccine; 2016 Dec; 34(51):6518-6528. PubMed ID: 27155494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax.
    Peterson JW; Comer JE; Noffsinger DM; Wenglikowski A; Walberg KG; Chatuev BM; Chopra AK; Stanberry LR; Kang AS; Scholz WW; Sircar J
    Infect Immun; 2006 Feb; 74(2):1016-24. PubMed ID: 16428748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs.
    Altboum Z; Gozes Y; Barnea A; Pass A; White M; Kobiler D
    Infect Immun; 2002 Nov; 70(11):6231-41. PubMed ID: 12379702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.
    Leffel EK; Bourdage JS; Williamson ED; Duchars M; Fuerst TR; Fusco PC
    Clin Vaccine Immunol; 2012 Aug; 19(8):1158-64. PubMed ID: 22695155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.
    Kao LM; Bush K; Barnewall R; Estep J; Thalacker FW; Olson PH; Drusano GL; Minton N; Chien S; Hemeryck A; Kelley MF
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3535-42. PubMed ID: 17065619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.
    Martin SW; Tierney BC; Aranas A; Rosenstein NE; Franzke LH; Apicella L; Marano N; McNeil MM
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):393-401. PubMed ID: 15717323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
    Heine HS; Bassett J; Miller L; Bassett A; Ivins BE; Lehoux D; Arhin FF; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3350-7. PubMed ID: 18606841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax.
    Fowler RA; Sanders GD; Bravata DM; Nouri B; Gastwirth JM; Peterson D; Broker AG; Garber AM; Owens DK
    Ann Intern Med; 2005 Apr; 142(8):601-10. PubMed ID: 15838066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.
    Vietri NJ; Tobery SA; Chabot DJ; Ingavale S; Somerville BC; Miller JA; Schellhase CW; Twenhafel NA; Fetterer DP; Cote CK; Klimko CP; Boyer AE; Woolfitt AR; Barr JR; Wright ME; Friedlander AM
    J Infect Dis; 2021 Feb; 223(2):319-325. PubMed ID: 32697310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.
    Gauthier YP; Tournier JN; Paucod JC; Corre JP; Mock M; Goossens PL; Vidal DR
    Infect Immun; 2009 Mar; 77(3):1197-207. PubMed ID: 19114543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
    Deziel MR; Heine H; Louie A; Kao M; Byrne WR; Basset J; Miller L; Bush K; Kelly M; Drusano GL
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5099-106. PubMed ID: 16304178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak.
    Brookmeyer R; Johnson E; Bollinger R
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):10129-32. PubMed ID: 12890865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001.
    Jefferds MD; Laserson K; Fry AM; Roy S; Hayslett J; Grummer-Strawn L; Kettel-Khan L; Schuchat A;
    Emerg Infect Dis; 2002 Oct; 8(10):1138-44. PubMed ID: 12396929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001.
    Williams JL; Noviello SS; Griffith KS; Wurtzel H; Hamborsky J; Perz JF; Williams IT; Hadler JL; Swerdlow DL; Ridzon R
    Emerg Infect Dis; 2002 Oct; 8(10):1133-7. PubMed ID: 12396928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.
    Ionin B; Hopkins RJ; Pleune B; Sivko GS; Reid FM; Clement KH; Rudge TL; Stark GV; Innes A; Sari S; Guina T; Howard C; Smith J; Swoboda ML; Vert-Wong E; Johnson V; Nabors GS; Skiadopoulos MH
    Clin Vaccine Immunol; 2013 Jul; 20(7):1016-26. PubMed ID: 23658392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From the Centers for Disease Control and Prevention. Additional options for preventive treatment for exposed persons to inhalational anthrax.
    JAMA; 2002 Feb; 287(5):579. PubMed ID: 11838446
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.